Key result
Atorvastatin 80 mg/day for 8 weeks increased angiopoietin-2 levels in all groups (P < .04), with a 3-fold increase in non-diabetics and a 2-fold increase in diabetics.
Why the study?
Does atorvastatin 80 mg/day improve endothelial, angiogenesis, and platelet function indices in South Asians and white Europeans with or without diabetes?
Observational
Does atorvastatin 80 mg/day improve endothelial, angiogenesis, and platelet function indices in South Asians and white Europeans with or without diabetes?
p-value: p=< .04
High-dose atorvastatin increases levels of the growth factor angiopoietin-2, suggesting an additional nonlipid effect that is attenuated in patients with diabetes.
High-dose atorvastatin may exert non-lipid angiogenic effects via angiopoietin-2, attenuated in diabetes; hypothesis-generating, needs randomized confirmation.
Lipid lowering with statins improves morbidity and mortality, particularly in diabetics, and may have additional nonlipid effects. South Asians (SAs) are at higher risk of cardiovascular disease and diabetes compared with white Europeans (WEs). We hypothesized that abnormal endothelial (marked by von Willebrand factor), angiogenesis (VEGF, angiopoietins 1 and 2) and platelet function (soluble P selectin, soluble CD40L) improve with statin treatment in diabetics in different ethnic groups. Plasma was obtained before and 8 weeks after treatment with atorvastatin (80 mg/day) by SAs and WEs with or without diabetes. Research indices were measured by enzyme-linked-immunosorbent assay (ELISA). Treatment increased angiopoietin-2 (P < .04) in all groups regardless of diabetes or ethnicity. In those free of diabetes, angiopoietin-2 increased 3-fold, whereas in diabetes, it increased 2-fold. We suggest that an additional effect of statins is to increase levels of growth factor angiopoietin-2 in the direction of normality. This effect is weaker in participants with diabetes.
No takes yet. Share an insight, caveat, or question.
Jaumdally et al. (2011) conducted an observational in Diabetes. Atorvastatin vs. Baseline was evaluated on Endothelial, angiogenesis, and platelet function indices (p=< .04). Atorvastatin 80 mg/day for 8 weeks increased angiopoietin-2 levels in all groups (P < .04), with a 3-fold increase in non-diabetics and a 2-fold increase in diabetics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: